Search

Your search keyword '"Chapman, Rebecca J"' showing total 22 results
Start Over Author "Chapman, Rebecca J"
22 results on '"Chapman, Rebecca J"'

2. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study

Author

Donson, Andrew M, primary, Bertrand, Kelsey C, additional, Riemondy, Kent A, additional, Gao, Dexiang, additional, Zhuang, Yonghua, additional, Sanford, Bridget, additional, Norris, Gregory A, additional, Chapman, Rebecca J, additional, Fu, Rui, additional, Willard, Nicholas, additional, Griesinger, Andrea M, additional, de Sousa, Graziella Ribeiro, additional, Amani, Vladimir, additional, Grimaldo, Enrique, additional, Hankinson, Todd C, additional, Booker, Ffyona, additional, Sill, Martin, additional, Grundy, Richard G, additional, Pajtler, Kristian W, additional, Ellison, David W, additional, Foreman, Nicholas K, additional, and Ritzmann, Timothy A, additional

Published
2023
Full Text
View/download PDF

8. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study

Author

Chapman, Rebecca J, primary, Ghasemi, David R, additional, Andreiuolo, Felipe, additional, Zschernack, Valentina, additional, Tauziede Espariat, Arnault, additional, Buttarelli, Francesca R, additional, Giangaspero, Felice, additional, Grill, Jacques, additional, Haberler, Christine, additional, Paine, Simon M L, additional, Scott, Ian, additional, Jacques, Thomas S, additional, Sill, Martin, additional, Pfister, Stefan, additional, Kilday, John-Paul, additional, Leblond, Pierre, additional, Massimino, Maura, additional, Witt, Hendrik, additional, Modena, Piergiorgio, additional, Varlet, Pascale, additional, Pietsch, Torsten, additional, Grundy, Richard G, additional, Pajtler, Kristian W, additional, and Ritzmann, Timothy A, additional

Published
2023
Full Text
View/download PDF

9. Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study

Author

Chapman, Rebecca J., primary, Ghasemi, David R., additional, Andreiuolo, Felipe, additional, Zschernack, Valentina, additional, Espariat, Arnault Tauziede, additional, Buttarelli, Francesca, additional, Giangaspero, Felice, additional, Grill, Jacques, additional, Haberler, Christine, additional, Paine, Simon M.L., additional, Scott, Ian, additional, Jacques, Thomas S., additional, Sill, Martin, additional, Pfister, Stefan, additional, Kilday, John-Paul, additional, Leblond, Pierre, additional, Massimino, Maura, additional, Witt, Hendrik, additional, Modena, Piergiorgio, additional, Varlet, Pascale, additional, Pietsch, Torsten, additional, Grundy, Richard G., additional, Pajtler, Kristian W., additional, and Ritzmann, Timothy A., additional

Published
2022
Full Text
View/download PDF

10. SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study

Author

Ritzmann, Timothy A, Chapman, Rebecca J, Kilday, John-Paul, Thorp, Nicola, Modena, Piergiorgio, Dineen, Robert A, Macarthur, Donald, Mallucci, Conor, Jaspan, Timothy, Pajtler, Kristian W, Giagnacovo, Marzia, Jacques, Thomas, Paine, Simon, Ellison, David, Bouffet, Eric, and Grundy, Richard G

Abstract

BackgroundSIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) of non-metastatic intracranial ependymoma in children aged 3 to 21 years treated with a staged management strategy. A further aim was to assess the response rate (RR) of subtotally resected (STR) ependymoma to vincristine, etoposide and cyclophosphamide (VEC). We report final results with 12-year follow-up and post hoc analyses of recently described biomarkers.Methods74 participants were eligible. Children with gross total resection (GTR) received radiotherapy, whilst those with STR received VEC before radiotherapy. DNA methylation, 1q, hTERT ,ReLA, Tenascin-C, H3K27me3 and pAKT status were evaluated.ResultsFive- and ten-year EFS was 49.5% and 46.7%, OS was 69.3% and 60.5%. GTR was achieved in 33/74 (44.6%) and associated with improved EFS (p=0.003, HR=2.6, 95% confidence interval (CI) 1.4-5.1). Grade 3 tumours were associated with worse OS (p=0.005, HR=2.8, 95%CI 1.3-5.8). 1q gain and hTERT expression were associated with poorer EFS (p=0.003, HR=2.70, 95%CI 1.49-6.10 and p=0.014, HR=5.8, 95%CI 1.2-28) and H3K27me3 loss with worse OS (p=0.003, HR=4.6, 95%CI 1.5-13.2). Methylation profiles showed expected patterns. 12 participants with STR did not receive chemotherapy; a protocol violation. However, best chemotherapy RR was 65.5% (19/29, 95%CI 45.7-82.1), exceeding the prespecified 45%.ConclusionsParticipants with totally resected ependymoma had the best outcomes. RR of STR to VEC exceeded the pre-specified efficacy criterion. However, cases of inaccurate stratification highlighted the need for rapid central review. 1q gain, H3K27me3 loss and hTERT expression were all associated with poorer survival outcomes.

Published
2022

11. SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study

Author

Ritzmann, Timothy A, primary, Chapman, Rebecca J, additional, Kilday, John-Paul, additional, Thorp, Nicola, additional, Modena, Piergiorgio, additional, Dineen, Robert A, additional, Macarthur, Donald, additional, Mallucci, Conor, additional, Jaspan, Timothy, additional, Pajtler, Kristian W, additional, Giagnacovo, Marzia, additional, Jacques, Thomas S, additional, Paine, Simon ML, additional, Ellison, David W, additional, Bouffet, Eric, additional, and Grundy, Richard G, additional

Published
2021
Full Text
View/download PDF

12. EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY

Author

A. Ritzmann, Timothy, primary, Chapman, Rebecca J, additional, Macarthur, Donald, additional, Mallucci, Conor, additional, Kilday, John-Paul, additional, Thorp, Nicola, additional, Modena, Piergiorgio, additional, Giagnacovo, Marzia, additional, Dineen, Rob, additional, Jaspan, Timothy, additional, Pajtler, Kristian W, additional, Jacques, Thomas S, additional, Paine, Simon M L, additional, Ellison, David W, additional, Bouffet, Eric, additional, and Grundy, Richard G, additional

Published
2021
Full Text
View/download PDF

13. EPEN-24. SIOP EPENDYMOMA II: CENTRAL EPENDYMOMA MANAGEMENT ADVISORY GROUP – THE UK EXPERIENCE

Author

Macarthur, Donald C, primary, Mallucci, Conor, additional, Kamaly-Asl, Ian, additional, Goodden, John, additional, Storer, Lisa C D, additional, Chapman, Rebecca J, additional, Kilday, J-P, additional, English, Martin, additional, Jaspan, Tim, additional, Chattopadhyay, Arpita, additional, Dineen, Rob A, additional, Avula, Shivaram, additional, Stivaros, Stavros, additional, and Grundy, Richard, additional

Published
2020
Full Text
View/download PDF

14. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups

Author

Ritzmann, Timothy A., primary, Rogers, Hazel A., additional, Paine, Simon M.L., additional, Storer, Lisa C.D., additional, Jacques, Thomas S., additional, Chapman, Rebecca J., additional, Ellison, David, additional, Donson, Andrew M., additional, Foreman, Nicholas K., additional, and Grundy, Richard G., additional

Published
2020
Full Text
View/download PDF

18. EPN-10UPDATING THE PROGNOSTIC IMPORTANCE OF RESECTION STATUS AND CHROMOSOME 1q GAIN IN CHILDREN TREATED ACCORDING TO THE FIRST SIOP 1999-04 TRIAL FOR PAEDIATRIC INTRACRANIAL EPENDYMOMA

Author

Kilday, John-Paul, primary, Chapman, Rebecca J., additional, Storer, Lisa C.D., additional, Lowe, James, additional, Jacques, Thomas S., additional, Jaspan, Tim, additional, MacArthur, Donald, additional, Mallucci, Conor, additional, Thorp, Nicky, additional, Massimino, Maura, additional, Bouffet, Eric, additional, Ellison, David, additional, Machin, David, additional, and Grundy, Richard G., additional

Published
2016
Full Text
View/download PDF

19. EPN-16THE SIOP II EPENDYMOMA MULTI-DISCIPLINARY ADVISORY GROUP (EMAG): THE UK APPROACH

Author

Storer, Lisa C.D., primary, Ritzmann, Timothy, additional, Chapman, Rebecca J., additional, Hanson, Mitzi, additional, Jaspan, Tim, additional, Dineen, Robert, additional, Avula, Shivaram, additional, Stivaros, Stavros, additional, MacArthur, Donald, additional, Mallucci, Conor, additional, Chakraborty, Aabir, additional, Aquilina, Kristian, additional, Kamaly-Asl, Ian, additional, Goodden, John, additional, Thorp, Nicky, additional, Whitfield, Gillian, additional, Paine, Simon, additional, Sehested, Astrid Marie, additional, Kilday, John-Paul, additional, English, Martin, additional, and Grundy, Richard G., additional

Published
2016
Full Text
View/download PDF

22. SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study.

Author

Ritzmann TA, Chapman RJ, Kilday JP, Thorp N, Modena P, Dineen RA, Macarthur D, Mallucci C, Jaspan T, Pajtler KW, Giagnacovo M, Jacques TS, Paine SML, Ellison DW, Bouffet E, and Grundy RG

Subjects
Child, Chromosome Aberrations, Cyclophosphamide, Etoposide, Follow-Up Studies, Humans, Treatment Outcome, Vincristine, Ependymoma genetics, Ependymoma pathology, Ependymoma therapy, Histones genetics
Abstract

Background: SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) of non-metastatic intracranial ependymoma in children aged 3-21 years treated with a staged management strategy. A further aim was to assess the response rate (RR) of subtotally resected (STR) ependymoma to vincristine, etoposide, and cyclophosphamide (VEC). We report final results with 12-year follow-up and post hoc analyses of recently described biomarkers., Methods: Seventy-four participants were eligible. Children with gross total resection (GTR) received radiotherapy, whilst those with STR received VEC before radiotherapy. DNA methylation, 1q, hTERT, ReLA, Tenascin-C, H3K27me3, and pAKT status were evaluated., Results: Five- and ten-year EFS was 49.5% and 46.7%, OS was 69.3% and 60.5%. GTR was achieved in 33/74 (44.6%) and associated with improved EFS (P = .003, HR = 2.6, 95% confidence interval (CI) 1.4-5.1). Grade 3 tumours were associated with worse OS (P = .005, HR = 2.8, 95%CI 1.3-5.8). 1q gain and hTERT expression were associated with poorer EFS (P = .003, HR = 2.70, 95%CI 1.49-6.10 and P = .014, HR = 5.8, 95%CI 1.2-28) and H3K27me3 loss with worse OS (P = .003, HR = 4.6, 95%CI 1.5-13.2). Methylation profiles showed expected patterns. 12 participants with STR did not receive chemotherapy; a protocol violation. However, best chemotherapy RR was 65.5% (19/29, 95%CI 45.7-82.1), exceeding the prespecified 45%., Conclusions: Participants with totally resected ependymoma had the best outcomes. RR of STR to VEC exceeded the pre-specified efficacy criterion. However, cases of inaccurate stratification highlighted the need for rapid central review. 1q gain, H3K27me3 loss, and hTERT expression were all associated with poorer survival outcomes., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results